Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.60 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 14/20 | 0.51 |
| ▸ | BRAF | P15056 | 13/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715763 | 0.95 | DDR2 (0.53) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1148513 | 0.92 | DDR2 (0.59) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1077857 | 0.89 | LCK (0.58) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1082084 | 0.88 | LCK (0.55) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1078974 | 0.88 | LCK (0.61) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1076596 | 0.88 | RAF1 (0.58) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL1149190 | 0.87 | DDR2 (0.55) | FGFR1DDR2LCKKDRJAK3 | |
| SCHEMBL1078464 | 0.85 | RAF1 (0.61) | LCKKDRJAK3MAPK14RAF1 | |
| SCHEMBL1080552 | 0.84 | LCK (0.64) | DDR2LCKKDRJAK3MAPK14 | |
| SCHEMBL1149686 | 0.84 | LCK (0.58) | FGFR1DDR2LCKKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | FGFR1 2218/4885DDR2 2179/4885LCK 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.